Personalis, Inc.
PSNL
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $1.8B
$17.20
▲ +2.20%
P/E
-15.78
Mkt Cap
$1.8B
52-Wk Range
$4.96–$18.89
52-Week Range
$4.96 - $18.89
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 223.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary NeXT Platform with integrated tumor and immune microenvironment analysis from minimal samples
- Advanced neoantigen prediction capabilities (NeXT SHERPA and NeXT NEOPS) for personalized cancer vaccines
- Strategic partnerships with Mayo Clinic and leading biopharmaceutical companies providing market validation
- Comprehensive data analytics combining genomics with AI for actionable clinical and research insights
- Liquid biopsy technology enabling non-invasive, real-time tumor monitoring for patient management
Bear Case
1 risk
- High volatility (beta 2.3). Larger-than-normal price swings expected.
Growth
Strong growth ahead
Expanding adoption of precision oncology and personalized medicine in cancer treatment
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Hot
+71.3% over 3m
Quality
Thin
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PSNL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of -$0.30 vs -$0.26 consensus (-13.9% surprise). Revenue of $22.4M vs $16.7M expected (+34.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-13.9%
Revenue trend · last 8Q
—
-15%
+6%
-24%
-44%
+3%
-25%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$25.7M
$16.8M
$20.6M
$17.2M
$14.5M
$17.3M
$15.5M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
6 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
67%
Sell
0%
Median Price Target
—
Latest: Craig-Hallum · Aug 24, 2026
vs Industry
How PSNL stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related